How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

260 results for

Adamantane

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Viral Factors Associated With the High Mortality Related to Human Infections With Clade 2.1 Influenza A/H5N1 Virus in Indonesia. Full Text available with Trip Pro

analyses were performed in specimens from 180 H5N1 patients, representing 90% of all Indonesian patients and 20% of reported H5N1-infected patients globally.H5N1 RNA was quantified in available upper- and lower-respiratory tract specimens as well as fecal and blood samples from 180 patients with confirmed infection between 2005 and 2017. Mutations in the neuraminidase and M2 genes that confer resistance to oseltamivir and adamantanes were assessed. Fatal and nonfatal cases were compared.High viral RNA

2019 Clinical Infectious Diseases

42. Memantine ratiopharm

6.1 of the SmPC. The product is available in Alu/Alu blisters or HDPE bottles as described in section 6.5 of the SmPC. 2.2.2. Active substance The active substance memantine (as hydrochloride) or 1-Amino-3,5-dimethyl tricycle (3,3,1,1 3,7 ) decane hydrochloride, 3,5-Dimethyl-1-adamantamine HCl, 1-Amino-3,5-dimethyl adamantane HCl is a white, crystalline powder, soluble in water and methanol, practically insoluble in acetone. It is a non-hygroscopic substance. Memantine contains two stereocenters

2013 European Medicines Agency - EPARs

43. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus

and a sulfonylurea and for whom insulin is not an option. 2. Drug plan costs for saxagliptin should not exceed the cost of other dipeptidyl peptidase-4 (DPP-4) inhibitors. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian

2014 Health Technology Assessment (HTA) Database.

44. Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus

complications of diabetes, specifically in patients who were unable to use insulin. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitorss Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600

2014 Health Technology Assessment (HTA) Database.

45. Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus

Subject indexing assigned by CRD MeSH Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitorss Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000844 Date

2014 Health Technology Assessment (HTA) Database.

46. Addendum to commission A13-17 (vildagliptin/metformin)

. Addendum zum auftrag A13-17 (vildagliptin/metformin). [Addendum to commission A13-17 (vildagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 189. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Metformin; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English

2014 Health Technology Assessment (HTA) Database.

47. Addendum to Commission A13-16 (vildagliptin)

to Commission A13-16 (vildagliptin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 188. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne

2014 Health Technology Assessment (HTA) Database.

48. Vildagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Vildagliptin – nutzenbewertung gemäß § 35a SGB V. [Vildagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 178. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors

2014 Health Technology Assessment (HTA) Database.

49. Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Metformins; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32014000013 Date abstract record published 09/01/2014 Health Technology Assessment (HTA) database

2014 Health Technology Assessment (HTA) Database.

50. Saxagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Adamantane; Diabetes Mellitus, Type 2; Dipeptidess; Dipeptidyl-Peptidase IV Inhibitors Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32014000037 Date abstract record published 10/01/2014 Health Technology Assessment (HTA) database Copyright © 2019 Institut

2014 Health Technology Assessment (HTA) Database.

51. Saxagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Saxagliptin – nutzenbewertung gemäß § 35a SGB V. [Saxagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 174. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV

2014 Health Technology Assessment (HTA) Database.

52. Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Metformin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32014000017 Date abstract record

2014 Health Technology Assessment (HTA) Database.

53. Saxagliptin (Onglyza®)

MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk AccessionNumber 32013001030 Date abstract record published 23/12/2013 Health Technology

2014 Health Technology Assessment (HTA) Database.

54. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis

of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis. Clinical Drug Investigation 2012; 32(3): 189-202 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adamantane /administration & Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /drug therapy; Dipeptides /administration & Dipeptidyl-Peptidase IV Inhibitors /administration & Drug Therapy, Combination; Female; Glipizide

2012 NHS Economic Evaluation Database.

55. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland Full Text available with Trip Pro

Technology and Therapeutics 2012; 14(1): 65-73 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adamantane /analogs & Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /blood /drug therapy /economics /epidemiology; Dipeptides /economics /therapeutic use; Dipeptidyl-Peptidase IV Inhibitors /therapeutic use; Drug Therapy, Combination /economics; Female; Hemoglobin A, Glycosylated /metabolism; Humans; Hypoglycemic Agents /economics /therapeutic use; Insulin, Isophane

2012 NHS Economic Evaluation Database.

56. Layer by Layer Mesoporous Silica-Hyaluronic Acid-Cyclodextrin Bifunctional “Lamination”: Study of the Application of Fluorescent Probe and Host–Guest Interactions in the Drug Delivery Field Full Text available with Trip Pro

Layer by Layer Mesoporous Silica-Hyaluronic Acid-Cyclodextrin Bifunctional “Lamination”: Study of the Application of Fluorescent Probe and Host–Guest Interactions in the Drug Delivery Field The layer-by-layer technique was exploited to adjust the magnitude of the host⁻guest interactions between adamantane and cyclodextrin. The effect depends on numerous complex and changeable growth profiles of the films and the number of bilayers. These composite films of mesoporous silica nanoparticles

2018 Materials

57. Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis Full Text available with Trip Pro

Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis Our previous studies indicated that adapentpronitrile, a new adamantane-based dipeptidyl peptidase-IV (DPP-IV) inhibitor, has a hypoglycemic effect and ameliorates rat pancreatic β cell dysfunction in type 2 diabetes mellitus through inhibiting DPP-IV activity. However, the effect of adapentpronitrile on the neurodegenerative

2018 Frontiers in cellular neuroscience

58. Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal‐Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging Full Text available with Trip Pro

, and photothermal effects. Herein, PDA nanoparticles are functionalized with β-cyclodextrin (CD) substitutions, which are further assembled with adamantane-modified arginine-glycine-aspartic acid (Ad-RGD) tripeptides to target integrin-rich tumor cells. The thus formed PDA-CD-RGD nanoparticles can deliver a phosphorescent iridium(III) complexes LysoIr ([Ir(ppy)2(l)]PF6, ppy = 2-phenylpyridine, L = (1-(2-quinolinyl)-β-carboline) to form a theranostic platform LysoIr@PDA-CD-RGD. It is demonstrated that LysoIr@PDA

2018 Advanced Science

59. Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells Full Text available with Trip Pro

occurring potassium ionophores (e.g. salinomycin) were shown to inhibit P-gp effectively. We have previously shown antitumour activity of a number of 18-crown-6 ether compounds that transport potassium ions across membranes. Here we present data on P-gp inhibitory activity of 16 adamantane-substituted monoaza- and diaza-18-crown-6 ether compounds, and their effect on MDR reversal in model cell lines. We show that crown ether activity depends on their lipophilicity as well as on the linker to adamantane

2018 Scientific reports

60. Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017 Full Text available with Trip Pro

Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017 Influenza causes high rates of morbidity and mortality. Genetic variability of influenza viruses generates resistance to antivirals, which are of two types, since they act on two different viral targets: adamantanes, which block the M2 ion channel, and the neuraminidase (NA) inhibitors.In Mexico, the available studies on the antiviral resistance of circulating influenza strains are scarce, so this work undertook

2018 Infection and drug resistance

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>